Emergency icon Important Updates

Maryam Valapour, MD, MPP

Maryam Valapour, MD, MPP
  • Watch Video
  • No ratings
  • 0 Patient Satisfaction Ratings
  • 0 Patient Comments
Department Pulmonary Medicine
Primary Location Cleveland Clinic Main Campus
Type of Doctor Adults Only
Languages English
Surgeon No


Is Cleveland Clinic Part of Your Insurance?

Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.

View All Plans

About Maryam Valapour, MD, MPP

Maryam Valapour, MD, MPP is Director of Lung Transplant Outcomes at the Respiratory Institute.

A practicing pulmonologist, Dr. Valapour has worked in the field of lung transplantation for 20 years and has extensive clinical expertise in the care of lung transplant candidates and recipients.

Dr. Valapour is focused on research to improve the U.S. lung transplant system and the outcomes of transplant patients. She serves as Principal Investigator on a number of grants addressing patient- and system-level approaches to improve survival from lung transplantation. Dr. Valapour holds an R01 grant from the National Institutes of Health to develop an improved risk-modeling approach to help prioritize patients with advanced lung diseases for lung transplant. She is the Principal Investigator for the Cystic Fibrosis Lung Transplant Consortium (CFLTC) award where the Cleveland Clinic is one of fifteen North American institutions participating in a clinical and translational network of Cystic Fibrosis (CF) lung transplant centers. The goal of this award is to facilitate lung transplant research for candidates and recipients with CF and other advanced lung diseases. Dr. Valapour is also Co-Principal Investigator for the CFLTC Biorepository Coordinating Center where she and her team of investigators provide scientific expertise and infrastructure to understand the pathogenesis of chronic transplant rejection and develop new therapies to improve outcomes for lung transplant patients.

In addition to her roles at the Cleveland Clinic, Dr. Valapour serves as Senior Investigator for Lung Transplantation for the U.S. Scientific Registry of Transplant Recipients (SRTR). In this role, she oversees the analysis of all U.S. lung transplant data and refinement of the lung allocation system. She serves as scientific advisor to the U.S. Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) Lung Committee.

Dr. Valapour earned her medical degree from the Medical University of South Carolina and completed residency in Internal Medicine at Thomas Jefferson University. She did fellowship training in Pulmonary and Critical Care Medicine at Johns Hopkins University. In addition, she completed fellowship training in Bioethics and Health Policy at Johns Hopkins University and earned a Master in Public Policy from Humphrey School of Public Affairs, University of Minnesota.

Education & Professional Highlights

Education & Professional Highlights


Education & Fellowships

Graduate School - University of Minnesota
Master of Public Policy
Minneapolis, MN

Fellowship - Johns Hopkins University
Pulmonary/Critical Care Medicine
Baltimore, MD

Fellowship - Johns Hopkins University
Bioethics/Health Policy
Baltimore, MD

Residency - Thomas Jefferson University Medical College
Internal Medicine
Philadelphia, PA

Medical Education - Medical University of South Carolina
Charleston, SC

Undergraduate - Charleston Southern University
Charleston, SC

Additional Training

  • Fellowship, Pulmonary and Critical Care (Johns Hopkins University)
  • Fellowship, Bioethics and Health Policy (Johns Hopkins University)
  • Master of Public Policy (University of Minnesota)

Professional Highlights

  • Senior Investigator for Lung Transplantation, Scientific Registry of Transplant Recipients (SRTR), Health Resources and Services Administration (2010-present)
  • Invited Expert and Reviewer for the National Academy of Science, Engineering and Medicine (NASEM) report "Realizing the Promise of Equity in the Organ Transplantation System (2022)
  • Member Board of Trustees, Ohio Solid Organ Transplantation Consortium (2021 - present)
  • Elected Member of Executive Committee, American Society of Transplantation (AST) Thoracic and Critical Care Community of Practice (2016-2018)
  • Chair, Research Committee of LifeSource Upper Midwest Organ Procurement Organization (2007-2014)


  • Internal Medicine - Pulmonary Disease

Specialty Interests

Lung Transplant

Awards & Honors

  • Fellow, American Society of Transplantation
  • Fellow, American College of Chest Physicians
  • University of Minnesota Champion of Care award for excellence in care of patients


  • International Society of Heart and Lung Transplantation
  • American Society of Transplantation
  • American Thoracic Society
Research & Publications

Research & Publications

See publications for Maryam Valapour, MD, MPP.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/14/2024, Dr. Valapour has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Back to Top